Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials

Zhou et al., PLOS ONE, doi:10.1371/journal.pone.0300512
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
26th treatment shown to reduce risk in November 2021
 
*, now with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
Meta analysis of 6 RCTs with 4,711 total participants showing significantly lower clinical deterioration and hospitalization with fluvoxamine treatment for COVID-19. Fluvoxamine doses ≥200mg daily were more effective than lower doses. There was no significant difference in adverse events or serious adverse events compared to placebo.
8 meta analyses show significant improvements with fluvoxamine for mortality1,2, hospitalization1,3-7, progression2,7, and severity8.
Currently there are 21 fluvoxamine for COVID-19 studies, showing 44% lower mortality [15‑63%], 42% lower ventilation [-151‑86%], 10% higher ICU admission [-72‑326%], 51% lower hospitalization [8‑73%], and 27% fewer cases [18‑35%].
Zhou et al., 16 May 2024, peer-reviewed, 5 authors. Contact: niyuehua1982@163.com.
This PaperFluvoxamineAll
The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials
Qiufeng Zhou, Guozheng Zhao, Yu Pan, Ying Zhang, Yuehua Ni
PLOS ONE, doi:10.1371/journal.pone.0300512
Background Recently, several randomized controlled trials (RCTs) of fluvoxamine have been successfully conducted for the treatment of patients with coronavirus disease 2019 . This systematic review and meta-analysis was to evaluate the efficacy and safety of fluvoxamine in patients with COVID-19. Methods MEDLINE, EMBASE, Cochrane Library and clinicaltrials.gov were searched for RCTs which were performed to evaluate fluvoxamine and placebo up to January 31, 2024. Review Manager 5.3 was used to perform meta-analysis. The risk ratio (RR) and mean difference (MD) was analyzed and calculated with a random effect model. Results We pooled 4,711 participants from six RCTs (2,382 in the fluvoxamine group and 2,329 in the placebo group). Compared to the placebo group, the fluvoxamine group had a significantly lower rate of clinical deterioration (RR, 0.73; P = 0.004; 95% CI, 0.59 to 0.90; I 2 = 0%) and hospitalization (RR, 0.76; P = 0.04; 95% CI, 0.59 to 0.99; I 2 = 0%). In the meantime, compared with the placebo group, fluvoxamine group did not show any higher risk of AEs (P = 0.13 and 0.91, respectively) in safety outcomes analysis. The subgroup analysis showed that fluvoxamine treatment performed more than 200 mg daily appears to be more effective than those performed less than 200 mg daily in reducing clinical deterioration and hospitalization risks, while not exhibiting higher AE and SAE risks than placebo group. Conclusion Fluvoxamine for patients with COVID-19, especially those who take 200 mg or more daily, is superior to the placebo group in reducing clinical deterioration and hospitalization, and did
Supporting information S1
References
Bhuta, Khokher, Kesireddy, Iftikhar, Beran et al., Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis, American journal of therapeutics, doi:10.1097/MJT.0000000000001496
Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2201662
Cheema, Jafar, Elrashedy, Shahid, Awan et al., Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis, J Infect, doi:10.1016/j.jinf.2022.10.012
Higgins, Altman, Gotzsche, Juni, Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ (Clinical research, doi:10.1136/bmj.d5928
Hillary, Ceasar, An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines, Heliyon, doi:10.1016/j.heliyon.2023.e13952
Hoertel, Sanchez-Rico, Cougoule, Gulbins, Kornhuber et al., Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms, Mol Psychiatry, doi:10.1038/s41380-021-01254-3
Ishima, Fujita, Hashimoto, Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells, Eur J Pharmacol, doi:10.1016/j.ejphar.2014.01.064
Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA network open, doi:10.1001/jamanetworkopen.2022.6269
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial, Jama, doi:10.1001/jama.2020.22760
Liberati, Altman, Tetzlaff, Mulrow, Gotzsche et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ (Clinical research
Marcec, Dodig, Likic, A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference, J Infect, doi:10.1016/j.jinf.2022.11.011
Mccarthy, Naggie, Boulware, Lindsell, Stewart et al., Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2022.24100
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, The Lancet, doi:10.1016/S0140-6736(20)30628-0
Nicol, Karp, Reiersen, Zorumski, Lenze, What Were You Before the War?" Repurposing Psychiatry During the COVID-19 Pandemic, The Journal of Clinical Psychiatry, doi:10.4088/JCP.20com13373
Reiersen, Mattar, Bender Ignacio, Boulware, Lee et al., The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial, Open Forum Infect Dis, doi:10.1093/ofid/ofad419
Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/S2214-109X(21)00448-4
Reis, Santos, Silva, Silva, Thabane et al., Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial, Ann Intern Med, doi:10.7326/M22-3305
Seo, Kim, Bae, Park, Chung et al., Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial, Infect Chemother, doi:10.3947/ic.2021.0142
Stewart, Rebolledo, Mourad, Lindsell, Boulware et al., Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial, JAMA, doi:10.1001/jama.2023.23363
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2021.652688
Yu, Carvalho, Thompson, Tsai, Tseng et al., Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection, Int J Environ Res Public Health, doi:10.3390/ijerph20054088
Zhu, Zhang, Li, Yang, Song, A Novel Coronavirus from Patients with Pneumonia in China, New England Journal of Medicine, doi:10.1056/NEJMoa2001017
{ 'indexed': {'date-parts': [[2024, 5, 17]], 'date-time': '2024-05-17T00:36:23Z', 'timestamp': 1715906183377}, 'reference-count': 23, 'publisher': 'Public Library of Science (PLoS)', 'issue': '5', 'license': [ { 'start': { 'date-parts': [[2024, 5, 16]], 'date-time': '2024-05-16T00:00:00Z', 'timestamp': 1715817600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [{'name': 'Wujiang Science, Education and Health Project', 'award': ['WWK202112']}], 'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False}, 'abstract': '<jats:sec id="sec001">\n' '<jats:title>Background</jats:title>\n' '<jats:p>Recently, several randomized controlled trials (RCTs) of fluvoxamine have been ' 'successfully conducted for the treatment of patients with coronavirus disease 2019 ' '(COVID-19). This systematic review and meta-analysis was to evaluate the efficacy and safety ' 'of fluvoxamine in patients with COVID-19.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec002">\n' '<jats:title>Methods</jats:title>\n' '<jats:p>MEDLINE, EMBASE, Cochrane Library and clinicaltrials.gov were searched for RCTs which ' 'were performed to evaluate fluvoxamine and placebo up to January 31, 2024. Review Manager 5.3 ' 'was used to perform meta-analysis. The risk ratio (RR) and mean difference (MD) was analyzed ' 'and calculated with a random effect model.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec003">\n' '<jats:title>Results</jats:title>\n' '<jats:p>We pooled 4,711 participants from six RCTs (2,382 in the fluvoxamine group and 2,329 ' 'in the placebo group). Compared to the placebo group, the fluvoxamine group had a ' 'significantly lower rate of clinical deterioration (RR, 0.73; P = 0.004; 95% CI, 0.59 to ' '0.90; I<jats:sup>2</jats:sup> = 0%) and hospitalization (RR, 0.76; P = 0.04; 95% CI, 0.59 to ' '0.99; I<jats:sup>2</jats:sup> = 0%). In the meantime, compared with the placebo group, ' 'fluvoxamine group did not show any higher risk of AEs (P = 0.13 and 0.91, respectively) in ' 'safety outcomes analysis. The subgroup analysis showed that fluvoxamine treatment performed ' 'more than 200 mg daily appears to be more effective than those performed less than 200 mg ' 'daily in reducing clinical deterioration and hospitalization risks, while not exhibiting ' 'higher AE and SAE risks than placebo group.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec004">\n' '<jats:title>Conclusion</jats:title>\n' '<jats:p>Fluvoxamine for patients with COVID-19, especially those who take 200 mg or more ' 'daily, is superior to the placebo group in reducing clinical deterioration and ' 'hospitalization, and did not show any higher risk of AEs and SAEs in safety concerns, which ' 'might be a promising intervention for COVID-19.</jats:p>\n' '</jats:sec>', 'DOI': '10.1371/journal.pone.0300512', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 16]], 'date-time': '2024-05-16T17:57:54Z', 'timestamp': 1715882274000}, 'page': 'e0300512', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and ' 'meta-analysis from randomized controlled trials', 'prefix': '10.1371', 'volume': '19', 'author': [ {'given': 'Qiufeng', 'family': 'Zhou', 'sequence': 'first', 'affiliation': []}, {'given': 'Guozheng', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yu', 'family': 'Pan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ying', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0009-0007-9514-0653', 'authenticated-orcid': True, 'given': 'Yuehua', 'family': 'Ni', 'sequence': 'additional', 'affiliation': []}], 'member': '340', 'published-online': {'date-parts': [[2024, 5, 16]]}, 'reference': [ { 'key': 'pone.0300512.ref001', 'unstructured': 'World Health Organization. WHO Coronavirus (COVID-19) Dashboard ' '[https://covid19.who.int]'}, { 'issue': '8', 'key': 'pone.0300512.ref002', 'doi-asserted-by': 'crossref', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A Novel Coronavirus from Patients with Pneumonia in China, 2019', 'volume': '382', 'author': 'N Zhu', 'year': '2020', 'journal-title': 'New England Journal of Medicine'}, { 'issue': '3', 'key': 'pone.0300512.ref003', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.heliyon.2023.e13952', 'article-title': 'An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and ' 'vaccines', 'volume': '9', 'author': 'VE Hillary', 'year': '2023', 'journal-title': 'Heliyon'}, { 'issue': '10229', 'key': 'pone.0300512.ref004', 'doi-asserted-by': 'crossref', 'first-page': '1033', 'DOI': '10.1016/S0140-6736(20)30628-0', 'article-title': 'COVID-19: consider cytokine storm syndromes and immunosuppression', 'volume': '395', 'author': 'P Mehta', 'year': '2020', 'journal-title': 'The Lancet'}, { 'issue': '3', 'key': 'pone.0300512.ref005', 'doi-asserted-by': 'crossref', 'DOI': '10.4088/JCP.20com13373', 'article-title': 'What Were You Before the War?” Repurposing Psychiatry During the ' 'COVID-19 Pandemic', 'volume': '81', 'author': 'GE Nicol', 'year': '2020', 'journal-title': 'The Journal of Clinical Psychiatry'}, { 'key': 'pone.0300512.ref006', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2021.652688', 'article-title': 'Fluvoxamine: A Review of Its Mechanism of Action and Its Role in ' 'COVID-19', 'volume': '12', 'author': 'VP Sukhatme', 'year': '2021', 'journal-title': 'Frontiers in Pharmacology'}, { 'key': 'pone.0300512.ref007', 'doi-asserted-by': 'crossref', 'first-page': '167', 'DOI': '10.1016/j.ejphar.2014.01.064', 'article-title': 'Interaction of new antidepressants with sigma-1 receptor chaperones and ' 'their potentiation of neurite outgrowth in PC12 cells', 'volume': '727', 'author': 'T Ishima', 'year': '2014', 'journal-title': 'Eur J Pharmacol'}, { 'issue': '12', 'key': 'pone.0300512.ref008', 'doi-asserted-by': 'crossref', 'first-page': '7098', 'DOI': '10.1038/s41380-021-01254-3', 'article-title': 'Repurposing antidepressants inhibiting the sphingomyelinase ' 'acid/ceramide system against COVID-19: current evidence and potential ' 'mechanisms', 'volume': '26', 'author': 'N Hoertel', 'year': '2021', 'journal-title': 'Mol Psychiatry'}, { 'issue': '22', 'key': 'pone.0300512.ref009', 'doi-asserted-by': 'crossref', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'article-title': 'Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With ' 'Symptomatic COVID-19: A Randomized Clinical Trial', 'volume': '324', 'author': 'EJ Lenze', 'year': '2020', 'journal-title': 'Jama'}, { 'issue': '1', 'key': 'pone.0300512.ref010', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/S2214-109X(21)00448-4', 'article-title': 'Effect of early treatment with fluvoxamine on risk of emergency care ' 'and hospitalisation among patients with COVID-19: the TOGETHER ' 'randomised, platform clinical trial', 'volume': '10', 'author': 'G Reis', 'year': '2022', 'journal-title': 'Lancet Glob Health'}, { 'issue': '1', 'key': 'pone.0300512.ref011', 'doi-asserted-by': 'crossref', 'first-page': '102', 'DOI': '10.3947/ic.2021.0142', 'article-title': 'Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a ' 'Community Treatment Center: A Preliminary Result of Randomized ' 'Controlled Trial', 'volume': '54', 'author': 'H Seo', 'year': '2022', 'journal-title': 'Infect Chemother'}, { 'issue': '4', 'key': 'pone.0300512.ref012', 'doi-asserted-by': 'crossref', 'first-page': '296', 'DOI': '10.1001/jama.2022.24100', 'article-title': 'Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in ' 'Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial', 'volume': '329', 'author': 'MW McCarthy', 'year': '2023', 'journal-title': 'JAMA'}, { 'issue': '8', 'key': 'pone.0300512.ref013', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/ofid/ofad419', 'article-title': 'The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With ' 'Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial', 'volume': '10', 'author': 'AM Reiersen', 'year': '2023', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '24', 'key': 'pone.0300512.ref014', 'doi-asserted-by': 'crossref', 'first-page': '2354', 'DOI': '10.1001/jama.2023.23363', 'article-title': 'Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients ' 'With COVID-19: The ACTIV-6 Randomized Clinical Trial', 'volume': '330', 'author': 'TG Stewart', 'year': '2023', 'journal-title': 'JAMA'}, { 'key': 'pone.0300512.ref015', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/bmj.b2700', 'article-title': 'The PRISMA statement for reporting systematic reviews and meta-analyses ' 'of studies that evaluate healthcare interventions: explanation and ' 'elaboration', 'volume': '339', 'author': 'A Liberati', 'year': '2009', 'journal-title': 'BMJ (Clinical research ed)'}, { 'key': 'pone.0300512.ref016', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/bmj.d5928', 'article-title': 'The Cochrane Collaboration’s tool for assessing risk of bias in ' 'randomised trials', 'volume': '343', 'author': 'JP Higgins', 'year': '2011', 'journal-title': 'BMJ (Clinical research ed)'}, { 'issue': '3', 'key': 'pone.0300512.ref017', 'doi-asserted-by': 'crossref', 'first-page': 'e298', 'DOI': '10.1097/MJT.0000000000001496', 'article-title': 'Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection ' 'and the Lack of Efficacy in Reducing Rates of Hospitalization, ' 'Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A ' 'Systematic Review and Meta-Analysis', 'volume': '29', 'author': 'S Bhuta', 'year': '2022', 'journal-title': 'American journal of therapeutics'}, { 'issue': '6', 'key': 'pone.0300512.ref018', 'doi-asserted-by': 'crossref', 'first-page': '702', 'DOI': '10.1016/j.jinf.2022.10.012', 'article-title': 'Efficacy and safety of fluvoxamine for the treatment of COVID-19 ' 'patients: A systematic review and meta-analysis', 'volume': '85', 'author': 'HA Cheema', 'year': '2022', 'journal-title': 'J Infect'}, { 'issue': '2', 'key': 'pone.0300512.ref019', 'doi-asserted-by': 'crossref', 'first-page': '154', 'DOI': '10.1016/j.jinf.2022.11.011', 'article-title': 'A meta-analysis regarding fluvoxamine and hospitalization risk of ' 'COVID-19 patients: TOGETHER making a difference', 'volume': '86', 'author': 'R Marcec', 'year': '2023', 'journal-title': 'J Infect'}, { 'issue': '4', 'key': 'pone.0300512.ref020', 'article-title': 'Fluvoxamine for Outpatient Management of COVID-19 to Prevent ' 'Hospitalization: A Systematic Review and Meta-analysis', 'volume': '5', 'author': 'TC Lee', 'year': '2022', 'journal-title': 'JAMA network open'}, { 'issue': '5', 'key': 'pone.0300512.ref021', 'article-title': 'Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on ' 'Clinical Deterioration in Adult Patients with Symptomatic COVID-19 ' 'Infection', 'volume': '20', 'author': 'CL Yu', 'year': '2023', 'journal-title': 'Int J Environ Res Public Health'}, { 'issue': '7', 'key': 'pone.0300512.ref022', 'doi-asserted-by': 'crossref', 'first-page': '599', 'DOI': '10.1056/NEJMoa2201662', 'article-title': 'Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19', 'volume': '387', 'author': 'CT Bramante', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': 'pone.0300512.ref023', 'doi-asserted-by': 'crossref', 'first-page': '667', 'DOI': '10.7326/M22-3305', 'article-title': 'Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset ' 'COVID-19: A Randomized Platform Trial', 'volume': '176', 'author': 'G Reis', 'year': '2023', 'journal-title': 'Ann Intern Med'}], 'container-title': 'PLOS ONE', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0300512', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 16]], 'date-time': '2024-05-16T17:58:15Z', 'timestamp': 1715882295000}, 'score': 1, 'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0300512'}}, 'subtitle': [], 'editor': [{'given': 'Sheikh Arslan', 'family': 'Sehgal', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2024, 5, 16]]}, 'references-count': 23, 'journal-issue': {'issue': '5', 'published-online': {'date-parts': [[2024, 5, 16]]}}, 'URL': 'http://dx.doi.org/10.1371/journal.pone.0300512', 'relation': {}, 'ISSN': ['1932-6203'], 'subject': [], 'container-title-short': 'PLoS ONE', 'published': {'date-parts': [[2024, 5, 16]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit